Abstract

Trachysperum ammi has been traditionally used for the treatment of neurological disorders such as depression and anxiety. To date, T. ammi has reported for its chemical constituents in different diseases condition. The traditional evidence convinced us to perform the antidepressant-like activity of methanolic extract of Trachysperum ammi (META). The antidepressant activity of META assessed by using forced swimming test (FST), tail suspension test (TST), and locomotor activity test. The seed parts of META at doses level of 50, 100 and 200 mg/kg body weight administered orally to examine the CNS stimulants activity test in mice behavioral models. Here, we reported that META significantly reduced immobility time in the FST after repeated administration of 50, 100 and 200 mg/kg to mice for 14 days. The intensity of immobility significantly reduced at all of the doses (p mg/kg for 14 days, respectively. Additionally, we were executed locomotor activity test to check the motor stimulating activity. META has employed at a dosage of 50, 100 and 200 mg/kg for 14 days, the results have found that 50 mg/kg produced the locomotion effects as similar to the control group. Interestingly, the locomotion, rearing, and defecation significantly (p Trachysperum ammi may possess antidepressant-like activity which may use as a supportive treatment to management of neurological disorders.

Highlights

  • Mental depression is a chronic mental disorder that distresses a person’s mood, thoughts, physical health, and behavior

  • The antidepressant activity of methanolic extract of Trachysperum ammi (META) assessed by using forced swimming test (FST), tail suspension test (TST), and locomotor activity test

  • Our present findings suggest that the seed parts of Trachysperum ammi may possess antidepressant-like activity which may use as a supportive treatment to management of neurological disorders

Read more

Summary

Introduction

Mental depression is a chronic mental disorder that distresses a person’s mood, thoughts, physical health, and behavior. World Health Report showed evidence that about 450 million people all over the world suffer from mental or behavioral syndrome [2]. It indicates about 12.3% of the worldwide burden of disease, and it may rise at 15% percent rate in 2020 [3]. Patients with major depressive disorder have symptoms that reflect changes in brain, monoamine neurotransmitters, norepinephrine, serotonin, dopamine [4]. It anticipated that in 2020, after cardiovascular disease, depression may place at the second greatest increase rate of morbidity as a socioeconomic burden [5]. The aim of this study was to find out a new antidepressant drug from the natural origin

Objectives
Methods
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.